Journal article
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
Cancers, Vol.14(23), p.6013
12/06/2022
DOI: 10.3390/cancers14236013
PMID: 36497493
Abstract
Despite the increasing implementation of targeted and immunotherapy-based treatments, the prognosis of patients with advanced NSCLC remains dismal. We prospectively evaluated longitudinal plasma cfDNA kinetics as an early marker of therapeutic efficacy in patients with advanced NSCLC undergoing standard first-line treatments.
From February 2020 to May 2022, treatment-naïve patients with advanced NSCLC were consecutively enrolled at the Medical Oncology Unit of the Paolo Giaccone University Hospital, Palermo (Italy). We quantified cfDNA in terms of ng/μL using a Qubit
dsDNA HS Assay Kit. The agreement between the cfDNA and radiologic response was evaluated from baseline (T0) to the radiologic evaluation (T1).
A total of 315 liquid biopsy samples were collected from 63 patients at baseline, with a total of 235 paired plasma samples from 47 patients at disease re-evaluation. A fair concordance was observed between early and durable radiographic and cfDNA response (Cohen's kappa coefficient = 0.001); 11 and 18 patients receiving TKI (Pearson's chi-squared test = 4.278; Cohen's kappa coefficient = 0.039) and IO treatments (Pearson's chi-squared test = 7.481; Cohen's kappa coefficient = 0.006) showed a significant and durable association between cfDNA dynamics and the first radiologic evaluation, whereas among the 18 patients undergoing CT, no significant correlation was observed (Pearson's chi-squared test = 0.720; Cohen's kappa coefficient = 0.396). The ECOG-PS 2 patients presented with the mean baseline cfDNA levels 2.6-fold higher than those with ECOG-PS 0-1 (1.71 vs. 0.65 ng/µL;
= 0.105).
Our real-world study demonstrates that quantitative changes in cfDNA values correlated with responses to therapy and relapse of disease in treatment-naïve patients with advanced NSCLC undergoing TKI- and IO-based treatments.
Details
- Title: Subtitle
- Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
- Creators
- Valerio Gristina - University of PalermoNadia Barraco - University of PalermoMaria La Mantia - University of PalermoLuisa Castellana - University of PalermoLavinia Insalaco - University of PalermoMarco Bono - University of PalermoAlessandro Perez - University of PalermoDelia Sardo - University of PalermoSara Inguglia - University of PalermoFederica Iacono - University of PalermoSofia Cutaia - University of PalermoTancredi Didier Bazan Russo - Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, ItalyEdoardo Francini - University of FlorenceLorena Incorvaia - University of PalermoGiuseppe Badalamenti - University of PalermoAntonio Russo - University of PalermoAntonio Galvano - University of PalermoViviana Bazan - University of Palermo
- Resource Type
- Journal article
- Publication Details
- Cancers, Vol.14(23), p.6013
- DOI
- 10.3390/cancers14236013
- PMID
- 36497493
- NLM abbreviation
- Cancers (Basel)
- ISSN
- 2072-6694
- eISSN
- 2072-6694
- Language
- English
- Date published
- 12/06/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221141802771
Metrics
2 Record Views